Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia




Patients with hematologic malignancies frequently become thrombocytopenic as a result of their underlying malignancy or treatments, including cytotoxic chemotherapy and hematopoietic stem cell transplantation and are at increased risk of hemorrhage. Prophylactic platelet transfusions are aimed at preventing severe or life-threatening hemorrhage. This review summarizes recent evidence, including the need for prophylactic platelet transfusions, the optimal dose, platelet transfusion triggers, and risk factors for bleeding. It also discusses controversies surrounding platelet transfusions in this population.


Key points







  • •

    A uniform prophylactic platelet transfusion strategy for all patients with thrombocytopenia is not appropriate.


  • •

    Patients may have significant bleeding at platelet counts of greater than 10 × 10 9 /L and should be assessed and managed on clinical grounds, not platelet count alone.


  • •

    Platelet count is not the only factor that contributes to a patient’s propensity to bleed.


  • •

    Patients with acute leukemia should receive prophylactic platelet transfusions when their platelet count is less than 10 × 10 9 /L to prevent clinical bleeding.


  • •

    Greater consistency in the assessment and documentation of bleeding across transfusion trials is essential to support comparisons of outcomes between studies.






Introduction


Duke reported the first description of bleeding in the setting of thrombocytopenia, which improved after blood transfusion and recurred when the platelet count decreased. Up to 70% of patients with hematologic malignancy will have clinically significant bleeding (World Health Organization [WHO] grade 2 or higher) and up to 10% will have severe or life-threatening bleeding.


Patients have a tendency to develop bleeding symptoms as their platelet counts decrease, and major bleeding occurs more frequently at platelet counts of less than 10 × 10 9 /L. However, many patients with severe thrombocytopenia do not develop clinically significant bleeding. Conversely, major and even fatal bleeding is well-recognized to occur at platelet counts of greater than 10 × 10 9 /L.


In early leukemia studies, bleeding as a result of thrombocytopenia was a major contributing factor to mortality rates. Platelet transfusions helped to decrease the incidence of death attributable to bleeding and today mortality as a result of thrombocytopenia-related bleeding is exceedingly rare ( Table 1 ). Platelet transfusions have become an important adjunctive therapy and led to improved patient survival. They have also supported delivery of more intensive chemotherapy regimens.



Table 1

Rates of clinically significant bleeding and death from bleeding in the platelet transfusion randomized, controlled trials
























































































































































































Trial Total Patients (n) Bleeding Scale Bleeding Assessment and Rates of Bleeding Deaths from Hemorrhage (n)
Therapeutic only vs prophylactic platelet transfusions
Solomon et al, 1978 31 Not defined Not reported 0
Sintnicolaas et al, 1982 12 Not defined Not reported 0
Grossman et al, 1980 100 Study specific
Mild (not requiring active intervention) vs severe 		Mild Severe 14 e
86 (86%) 74 (74%)
Murphy et al, 1982 56 Study specific Clinically significant bleeding event 3
21 bleeds from study enrollment until study closure (37.5%)
15 bleeds in the first 10 mo of the study (27%)
Wandt et al, 2012 396 Modified WHO WHO grade 2 Grade 3 Grade 4 2
Reported per treatment cycle 10 (2.5%) 18 (4.5%)
Stanworth et al, 2013 600 Modified WHO WHO grade 2 Grade 3 Grade 4 0
272 (45%) 5 (0.8%) 2 (0.3%)
Platelet dose
Roy et al, 1973 62 Study specific Minor a Major b NR
18 (29%) 7 (11%)
Steffens et al, 2002 54 Not reported NR NR
Sensebé et al, 2005 101 WHO 1979 Hemorrhaging WHO grades 2–3 Grade 4 0
14 (14%) 5 (5%) NR
Tinmouth et al, 2004 111 Modified GIMEMA Minor Major 0
33 (30%) 10 (9%)
Heddle et al, 2009 129 Modified WHO WHO grade 2 Grade 3 Grade 4 0
56 (43%) 11 (8.5%) 3 (2.3%)
Slichter et al, 2010 1351 Modified WHO WHO grade 2 Grade 3 Grade 4 1
177 (13%) 24 (1.8%) 7 (0.5%)
Platelet trigger
Heckman et al, 1997 78 Ajani 1990 Any bleeding event Significant bleeding event 0
72 (92%) 24 (31%)
Rebulla et al, 1997 255 Study specific
GIMEMA scale 		Major 1
53 (21%)
Zumberg et al, 2002 159 Modified GIMEMA Minor c Major d 0
128 (8%) 25 (16%)
Diedrich et al, 2005 166 WHO 1979 WHO grade 2 Grades 3–4 1
19 (11%) 8 (4.8%)
Platelets vs other product
Higby et al, 1974 21 Study specific Hemorrhage Serious bleeding 0
13 (6%) 9 (4%)

Abbreviations: GIMEMA, Gruppo Italiano Malattie Ematologiche Dell’Adulto; NR, not reported; WHO, World Health Organization.

Data from Refs.

a Skin, mucous membranes of mouth, lips, gums, epistaxis.


b Genitourinary and Gastrointestinal tracts.


c Minor bleeding events (petechial, mucosal, and microscopic bleeding) as well as melena and hematemesis not requiring red blood cell (RBC) transfusion.


d Major bleeding events (gross hematuria, any bleed requiring RBC), retinal bleeding, or central nervous system bleeding.


e Bacterial and/or fungal sepsis were a contributing factor in 8 of these deaths.



Platelet concentrates are the second most commonly prescribed blood product after red blood cells (RBC) and hematooncology patients are the largest users of platelet concentrates. Platelet transfusion rates are increasing; in the United States, more than 2 million platelet units were transfused in 2011, a 7.3% increase compared with 2008. Platelet transfusions may be given therapeutically, to treat bleeding when thrombocytopenia or abnormal platelet function are contributing factors, but are more frequently given prophylactically, in efforts to avert bleeding before a procedure or when the platelet count falls below a certain threshold. Many patients with platelet counts of less than 10 × 10 9 /L will not have clinically significant bleeding, and therefore many platelet transfusions may be being given unnecessarily.




Introduction


Duke reported the first description of bleeding in the setting of thrombocytopenia, which improved after blood transfusion and recurred when the platelet count decreased. Up to 70% of patients with hematologic malignancy will have clinically significant bleeding (World Health Organization [WHO] grade 2 or higher) and up to 10% will have severe or life-threatening bleeding.


Patients have a tendency to develop bleeding symptoms as their platelet counts decrease, and major bleeding occurs more frequently at platelet counts of less than 10 × 10 9 /L. However, many patients with severe thrombocytopenia do not develop clinically significant bleeding. Conversely, major and even fatal bleeding is well-recognized to occur at platelet counts of greater than 10 × 10 9 /L.


In early leukemia studies, bleeding as a result of thrombocytopenia was a major contributing factor to mortality rates. Platelet transfusions helped to decrease the incidence of death attributable to bleeding and today mortality as a result of thrombocytopenia-related bleeding is exceedingly rare ( Table 1 ). Platelet transfusions have become an important adjunctive therapy and led to improved patient survival. They have also supported delivery of more intensive chemotherapy regimens.



Table 1

Rates of clinically significant bleeding and death from bleeding in the platelet transfusion randomized, controlled trials
























































































































































































Trial Total Patients (n) Bleeding Scale Bleeding Assessment and Rates of Bleeding Deaths from Hemorrhage (n)
Therapeutic only vs prophylactic platelet transfusions
Solomon et al, 1978 31 Not defined Not reported 0
Sintnicolaas et al, 1982 12 Not defined Not reported 0
Grossman et al, 1980 100 Study specific
Mild (not requiring active intervention) vs severe 		Mild Severe 14 e
86 (86%) 74 (74%)
Murphy et al, 1982 56 Study specific Clinically significant bleeding event 3
21 bleeds from study enrollment until study closure (37.5%)
15 bleeds in the first 10 mo of the study (27%)
Wandt et al, 2012 396 Modified WHO WHO grade 2 Grade 3 Grade 4 2
Reported per treatment cycle 10 (2.5%) 18 (4.5%)
Stanworth et al, 2013 600 Modified WHO WHO grade 2 Grade 3 Grade 4 0
272 (45%) 5 (0.8%) 2 (0.3%)
Platelet dose
Roy et al, 1973 62 Study specific Minor a Major b NR
18 (29%) 7 (11%)
Steffens et al, 2002 54 Not reported NR NR
Sensebé et al, 2005 101 WHO 1979 Hemorrhaging WHO grades 2–3 Grade 4 0
14 (14%) 5 (5%) NR
Tinmouth et al, 2004 111 Modified GIMEMA Minor Major 0
33 (30%) 10 (9%)
Heddle et al, 2009 129 Modified WHO WHO grade 2 Grade 3 Grade 4 0
56 (43%) 11 (8.5%) 3 (2.3%)
Slichter et al, 2010 1351 Modified WHO WHO grade 2 Grade 3 Grade 4 1
177 (13%) 24 (1.8%) 7 (0.5%)
Platelet trigger
Heckman et al, 1997 78 Ajani 1990 Any bleeding event Significant bleeding event 0
72 (92%) 24 (31%)
Rebulla et al, 1997 255 Study specific
GIMEMA scale 		Major 1
53 (21%)
Zumberg et al, 2002 159 Modified GIMEMA Minor c Major d 0
128 (8%) 25 (16%)
Diedrich et al, 2005 166 WHO 1979 WHO grade 2 Grades 3–4 1
19 (11%) 8 (4.8%)
Platelets vs other product
Higby et al, 1974 21 Study specific Hemorrhage Serious bleeding 0
13 (6%) 9 (4%)

Abbreviations: GIMEMA, Gruppo Italiano Malattie Ematologiche Dell’Adulto; NR, not reported; WHO, World Health Organization.

Data from Refs.

a Skin, mucous membranes of mouth, lips, gums, epistaxis.


b Genitourinary and Gastrointestinal tracts.


c Minor bleeding events (petechial, mucosal, and microscopic bleeding) as well as melena and hematemesis not requiring red blood cell (RBC) transfusion.


d Major bleeding events (gross hematuria, any bleed requiring RBC), retinal bleeding, or central nervous system bleeding.


e Bacterial and/or fungal sepsis were a contributing factor in 8 of these deaths.



Platelet concentrates are the second most commonly prescribed blood product after red blood cells (RBC) and hematooncology patients are the largest users of platelet concentrates. Platelet transfusion rates are increasing; in the United States, more than 2 million platelet units were transfused in 2011, a 7.3% increase compared with 2008. Platelet transfusions may be given therapeutically, to treat bleeding when thrombocytopenia or abnormal platelet function are contributing factors, but are more frequently given prophylactically, in efforts to avert bleeding before a procedure or when the platelet count falls below a certain threshold. Many patients with platelet counts of less than 10 × 10 9 /L will not have clinically significant bleeding, and therefore many platelet transfusions may be being given unnecessarily.




Methods


This review provides an update of the literature and some of the challenges raised by a very recent update of a Cochrane systematic review. The methodology of this update has been described elsewhere; in brief, searching for platelet transfusion trials multiple datasets was undertaken. Eligible trials were identified and data abstracted, alongside an assessment of risk of bias. The update of an earlier Cochrane review aimed to determine whether therapeutic-only platelet transfusions were as effective and safe as prophylactic platelet transfusions in patients with hematologic disorders undergoing cytotoxic chemotherapy or hematopoietic stem cell transplantation (HSCT). Seven randomized controlled trials (RCTs) met the predefined selection criteria (one is still ongoing), leaving a total of 6 eligible trials and a total of 1195 participants. These trials were conducted over a 35-year time period. Five studies contained separate data for each arm and were able to be critically appraised. Only 1 study was deemed to be at low risk of bias.




Main findings for review


For the systematic review’s primary outcome (number of patients with ≥1 bleeding episode within 30 days) significant heterogeneity was noted ( I 2 = 88%). This heterogeneity may reflect in part the different methodology and grading systems used to analyze and categorize bleeding in the individual studies. Four studies in the review reported clinically significant bleeding events and all showed a similar effect: higher rates of bleeding in participants receiving therapeutic-only platelet transfusions. Major differences were noted between studies, including platelet transfusion indications, RBC transfusion policy, and study endpoints, as well as classification of bleeding events. Individual studies also reported bleeding outcomes over different time periods and used different units of analysis. For these reasons a metaanalysis was unable to be performed.


Time to first bleeding episode was reported by 2 studies and again metaanalysis was unable to be performed because of heterogeneity ( I 2 = 90%). Individually, both studies showed that time to first bleeding episode was shorter in patients receiving therapeutic-only platelet transfusions. One study reported the number of days with clinically significant bleeding events per patient and this was statistically higher in the therapeutic-only transfusion group.


Owing to low mortality rates and rates of WHO grade 3 and 4 bleeding, there was insufficient evidence to determine whether there was any difference between platelet transfusion strategies for these outcomes. Three studies reported higher numbers of patients with WHO grade 3 or 4 bleeding events in the therapeutic-only transfusion group; however, a significant difference was not demonstrated, reflecting the rarity of this outcome.




Recent trials


The systematic review included the results of 2 recent, large, multicenter RCTs; the Trial of Prophylactic versus No-Prophylactic Platelet Transfusions (TOPPS) and the trial by Wandt and colleagues. Bleeding events were graded and reported differently in the trials; each trial used their own modification of the WHO bleeding scale and the same bleeding event would have been classified differently between studies ( Table 2 ). TOPPS reported that WHO grade 2 to 4 bleeding events occurred in 50% of patients in the therapeutic-only platelet transfusion group compared with 43% in the prophylaxis group; P = .06 for noninferiority, indicating that a therapeutic-only strategy was noninferior to prophylactic platelet transfusions. Analysis of TOPPS data by the systematic review found that although there seemed to be an increased risk of bleeding events with a therapeutic-only transfusion policy, the 95% CI crossed 1.0 (relative risk [RR], 1.17; 95% CI, 0.99–1.39). In the study by Wandt and colleagues, therapeutic-only transfusions were associated with an increased risk of WHO grade 2 to 4 bleeding events per treatment cycle ( P <.0001).



Table 2

Platelet transfusion randomized, controlled trials with study adaptations of the WHO bleeding scale




















































WHO Grade 3 WHO Grade 4
Heddle et al, 2009


  • Oral, nasal, skin, musculoskeletal, GI, GU, pulmonary, invasive sites, other




    • Bleeding requiring RBC transfusion specifically for support of bleeding within 24 hours of onset.





  • Any source




    • Fatal bleeding



    • Debilitating bleeding





  • Retinal b




    • —





  • Retinal




    • Retinal bleeding with visual impairment





  • CNS




    • —





  • CNS




    • Nonfatal CNS bleeding


Wandt et al, 2012


  • Oral, nasal, skin, musculoskeletal, GI, GU, pulmonary, invasive sites, other




    • Bleeding necessitating RBC transfusion over routine needs within 24 hours





  • Oral, nasal, skin, musculoskeletal, GI, GU, pulmonary, invasive sites, other




    • Bleeding necessitating RBC transfusion and associated with severe hemodynamic instability necessitating ICU





  • Retinal




    • Routine fundoscopy without visual impairment





  • Retinal




    • Bleeding with visual impairment proven by fundoscopy





  • CNS




    • —





  • CNS




    • Fatal or nonfatal CNS bleeding


Slichter et al, 2010


  • Oral, nasal, skin, musculoskeletal, GI, GU, pulmonary




    • Bleeding requiring RBC transfusion over routine transfusion needs a





  • Any site




    • Fatal bleeding



    • Bleeding associated with severe hemodynamic instability and requiring RBC transfusion over routine transfusion needs





  • Body cavity




    • Grossly bloody body cavity fluids and organ dysfunction with symptoms, and/or need to intervene (eg, to aspirate).





  • Retinal b




    • —





  • Retinal




    • Bleeding with visual impairment





  • CNS




    • LP with visible blood in absence of symptoms, and nontraumatic tap





  • CNS




    • CNS symptoms with nontraumatic bloody LP



    • CNS bleeding on imaging with or without dysfunction


Stanworth et al, 2013


  • Oral, nasal, skin, musculoskeletal, GI, GU, pulmonary, invasive sites




    • Bleeding requiring RBC transfusion specifically for support of bleeding within 24 hours of onset and without hemodynamic instability





  • Any site




    • Fatal bleeding any source



    • Debilitating bleeding



    • Bleeding associated with hemodynamic instability





  • Body cavity




    • Bleeding in body cavity fluids grossly visible





  • Retinal bleeding b




    • —





  • Retinal bleeding




    • Retinal bleeding and visual impairment





  • CNS




    • Cerebral bleeding noted on CT without neurologic signs and symptoms





  • CNS




    • Nonfatal cerebral bleeding with neurologic signs and symptoms


Only gold members can continue reading. Log In or Register to continue

Related posts:

Default ThumbnailAutologous Stem Cell Mobilization and Collection Default ThumbnailManagement of Patients with Sickle Cell Disease Using Transfusion Therapy Default ThumbnailModifications to Blood Components Default ThumbnailTransfusion Considerations in Pediatric Hematology and Oncology Patients Transfusion Reactions Default ThumbnailAssessing the Rationale and Effectiveness of Frozen Plasma Transfusions

Stay updated, free articles. Join our Telegram channel
Tags:
Mar 1, 2017 | Posted by in HEMATOLOGY | Comments Off on Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia

Full access? Get Clinical Tree
Get Clinical Tree app for offline access